Modified Rekovelle and Menopur Combination Protocol to Avoid Monitoring Before Day 10 of Stimulation
NCT ID: NCT05737979
Last Updated: 2024-02-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
772 participants
OBSERVATIONAL
2023-01-27
2024-01-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
As a standard practice for OHSS prevention at clinique ovo, women undergoing IVF will have a scheduled ultrasound and blood test on the sixth day of their stimulation treatment. However, with the determination of the Rekovelle and Menopur algorithm, the risks of OHSS before the tenth day have been considerably minimized.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Menopur And Rekovelle Combination Study Version 2.0
NCT06997900
Menopur And Rekovelle Combination Study
NCT03483545
Study to Assess the Design of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation or Intracytoplasmic Sperm Injection Procedures in Routine Clinical Practice
NCT04503707
Real-world Evidence on Follitropin Delta Individual Dosing
NCT05173597
Personalized Insemination Treatment Study
NCT03830723
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Women undergoing IVF
Women undergoing an antagonist in vitro fertilization cycle using Rekovelle and Menopur for stimulation
Study chart review
Evaluation of the IVF cycle using the prescribed medication
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Study chart review
Evaluation of the IVF cycle using the prescribed medication
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Antagonist IVF cycle using combination of Rekovelle and Menopur for stimulation according to the modified protocol employed at clinique ovo without deviation
* Presence of both ovaries
Exclusion Criteria
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Clinique Ovo
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jacques Kadoch, MD
Role: PRINCIPAL_INVESTIGATOR
Clinique Ovo
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinique Ovo
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3189
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.